Diclofenac Suppository to Control Pain During Flexible Cystoscopy

Model scores of the 29,894 trials active now.

Model score 8% for any early termination, 4% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 14% of the time (453 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2013-08-31. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Accepts healthy volunteers: Yes (lowers risk) · Who can join
• Sponsor's past termination rate: 0% (lowers risk) · Sponsor's track record
• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: painusecontrolsolutiondouble
  Phrases that lowered it: patientsantiurinaryliverinflammatory
• Phase: 2 (raises risk) · Design
• Minimum age: 18 (raises risk) · Who can join
• Responsible party: principal investigator (lowers risk) · Design
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Drug's FAERS reports with a death: 11.5% (lowers risk) · Drug's FDA history
• Disease area, neurology: Yes (raises risk) · Disease area
• Has a data monitoring committee: Yes (raises risk) · Design
• Primary purpose: treatment (raises risk) · Design
• Disease area, cancer: No (lowers risk) · Disease area
• Design: parallel (raises risk) · Design
• Sponsor's past trials: 40 (lowers risk) · Sponsor's track record
• Drug's FAERS reports marked serious: 87.9% (raises risk) · Drug's FDA history
• Blinding: double (raises risk) · Design
• Trials the sponsor started in the prior 2 years: 15 (lowers risk) · Sponsor's track record
• Maximum age: not given (raises risk) · Who can join
• Sex: male (lowers risk) · Who can join
• Collaborators: 0 (raises risk) · Design
• Number of arms: 2 (raises risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Efficacy of Preprocedural Diclofenac in Males Undergoing Double J Stent Removal Under Local Anesthesia NCT02598102 · started 2015 · scored riskier than 18% of active trials completed
• Intranasal Fentanyl for Management of Pain Associated With Cystoscopic Procedures NCT01756651 · started 2013 · scored riskier than 14% of active trials completed
• Efficacy of Diclofenac Suppository for Pain Control in Ultrasound Guided Biopsy of Prostate NCT01939743 · started 2011 · scored riskier than 11% of active trials completed
• A Study of Blue Light Flexible Cystoscopy With Cysview in the Detection of Bladder Cancer in the Surveillance Setting NCT02560584 · started 2015 · scored riskier than 69% of active trials completed
• Oral Hyoscine Butyl Bromide Versus Diclofenac Potassium Before Office Hysteroscopy NCT02714699 · started 2016 · scored riskier than 5% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.